Boysen G, Overgaard K, Sperling B, Pedersen H, Gam J, Ellemann K
Department of Neurology, University Hospital, Rigshospitalet, Odense, Denmark.
Z Kardiol. 1993;82 Suppl 2:105-8.
In the period from October 1990 to December 1991, 23 patients with acute ischemic stroke were treated with recombinant tissue plasminogen activator (rt-PA) at a median of 205 min (range 78-355 min) after symptom onset. In this open pilot study rt-PA was given intravenously after an acute CT scan had not shown acute changes. In 12 patients regional cerebral blood flow was measured intravenously using 99mTc-HMPAO before and within 24 h after thrombolytic therapy. Reperfusion of the ischemic area was obtained in 10 patients. In these patients clinical improvement was greater the shorter the delay from symptom onset to initiation of treatment. Three of the 23 patients died, one of a parenchymatous hematoma, one of a large middle cerebral artery infarct, and one of acute myocardial infarction.
在1990年10月至1991年12月期间，23例急性缺血性卒中患者在症状发作后中位时间205分钟（范围78 - 355分钟）接受了重组组织型纤溶酶原激活剂（rt-PA）治疗。在这项开放性初步研究中，急性CT扫描未显示急性改变后，静脉给予rt-PA。12例患者在溶栓治疗前及治疗后24小时内静脉注射99mTc-HMPAO测量局部脑血流量。10例患者实现了缺血区域再灌注。在这些患者中，从症状发作到开始治疗的延迟时间越短，临床改善越大。23例患者中有3例死亡，1例死于实质性血肿，1例死于大脑中动脉大面积梗死，1例死于急性心肌梗死。
